BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: O'Leary JG, Cai J, Freeman R, Banuelos N, Hart B, Johnson M, Jennings LW, Kaneku H, Terasaki PI, Klintmalm GB. Proposed Diagnostic Criteria for Chronic Antibody-Mediated Rejection in Liver Allografts. Am J Transplant. 2016;16:603-614. [PMID: 26469278 DOI: 10.1111/ajt.13476] [Cited by in Crossref: 64] [Cited by in F6Publishing: 47] [Article Influence: 9.1] [Reference Citation Analysis]
Number Citing Articles
1 Lee BT, Fiel MI, Schiano TD. Antibody-mediated rejection of the liver allograft: An update and a clinico-pathological perspective. J Hepatol 2021:S0168-8278(21)01957-7. [PMID: 34343613 DOI: 10.1016/j.jhep.2021.07.027] [Reference Citation Analysis]
2 Demetris AJ. Longterm outcome of the liver graft: The pathologist's perspective. Liver Transpl 2017;23:S70-5. [DOI: 10.1002/lt.24851] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
3 O'Leary JG. Donor-specific alloantibodies in liver transplantation: how should we define and improve long-term success? Transpl Int 2015;28:1359-61. [PMID: 26284821 DOI: 10.1111/tri.12661] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Neil DA, Bellamy CO, Smith M, Haga H, Zen Y, Sebagh M, Ruppert K, Lunz J, Hübscher SG, Demetris AJ. Global quality assessment of liver allograft C4d staining during acute antibody-mediated rejection in formalin-fixed, paraffin-embedded tissue. Human Pathology 2018;73:144-55. [DOI: 10.1016/j.humpath.2017.12.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
5 Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34:171-354. [PMID: 31180581 DOI: 10.1002/jca.21705] [Cited by in Crossref: 314] [Cited by in F6Publishing: 277] [Article Influence: 104.7] [Reference Citation Analysis]
6 Wood-Trageser MA, Lesniak AJ, Demetris AJ. Enhancing the Value of Histopathological Assessment of Allograft Biopsy Monitoring. Transplantation 2019;103:1306-22. [PMID: 30768568 DOI: 10.1097/TP.0000000000002656] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
7 Wu Y, Huang M, Sun H, Zhou X, Zhou R, Gu G, Xia Q. Role of Innate Immunity in Pediatric Post-transplant Idiopathic Liver Fibrosis. Front Immunol 2020;11:2111. [PMID: 33193293 DOI: 10.3389/fimmu.2020.02111] [Reference Citation Analysis]
8 Valenzuela NM, Hickey MJ, Reed EF. Antibody Subclass Repertoire and Graft Outcome Following Solid Organ Transplantation. Front Immunol 2016;7:433. [PMID: 27822209 DOI: 10.3389/fimmu.2016.00433] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
9 Sheikh A, Chau KY, Evans HM. Histological findings in protocol biopsies following pediatric liver transplant: Low incidence of abnormalities at 5 years. Pediatr Transplant. 2018;22:e13212. [PMID: 29749699 DOI: 10.1111/petr.13212] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Clemente MG, Antonucci R, Mandato C, Cicotto L, Meloni A, Gridelli B, De Virgiliis S, Manns MP, Vajro P. Autoantibodies against CYP-2C19: A Novel Serum Marker in Pediatric De Novo Autoimmune Hepatitis? Biomed Res Int 2017;2017:3563278. [PMID: 29279846 DOI: 10.1155/2017/3563278] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Guerra MR, Naini BV, Scapa JV, Reed EF, Busuttil RW, Cheng EY, Farmer DG, Vargas JH, Venick RS, McDiarmid SV, Wozniak LJ. Obliterative portal venopathy: A histopathologic finding associated with chronic antibody-mediated rejection in pediatric liver allografts. Pediatr Transplant. 2018;22. [PMID: 29363222 DOI: 10.1111/petr.13124] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
12 Stevenson HL, Prats MM, Isse K, Zeevi A, Avitzur Y, Ng VL, Demetris AJ. Isolated vascular “v” lesions in liver allografts: How to approach this unusual finding. Am J Transplant 2018;18:1534-43. [DOI: 10.1111/ajt.14708] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Mccaughan JA, Robertson V, Falconer SJ, Cryer C, Turner DM, Oniscu GC. Preformed donor-specific HLA antibodies are associated with increased risk of early mortality after liver transplantation. Clin Transplant 2016;30:1538-44. [DOI: 10.1111/ctr.12851] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
14 Herzer K, Sterneck M, Welker MW, Nadalin S, Kirchner G, Braun F, Malessa C, Herber A, Pratschke J, Weiss KH, Jaeckel E, Tacke F. Current Challenges in the Post-Transplant Care of Liver Transplant Recipients in Germany. J Clin Med 2020;9:E3570. [PMID: 33167567 DOI: 10.3390/jcm9113570] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Gül-Klein S, Hegermann H, Röhle R, Schmelzle M, Tacke F, Schöning W, Öllinger R, Dziodzio T, Maier P, Plewe JM, Horst D, Sauer IM, Pratschke J, Lachmann N, Eurich D. Donor-Specific Antibodies Against Donor Human Leukocyte Antigen are Associated with Graft Inflammation but Not with Fibrosis Long-Term After Liver Transplantation: An Analysis of Protocol Biopsies. J Inflamm Res 2021;14:2697-712. [PMID: 34188517 DOI: 10.2147/JIR.S307778] [Reference Citation Analysis]
16 Del Bello A, Congy-Jolivet N, Audry B, Antoine C, Esposito L, Hebral AL, Kamar N. Impact of transplant accessibility for sensitized patients by avoiding unacceptable antigens. Liver Transpl 2017;23:880-6. [PMID: 28477360 DOI: 10.1002/lt.24781] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Fiel MI, Schiano TD. Idiopathic noncirrhotic portal hypertension. Seminars in Diagnostic Pathology 2019;36:395-403. [DOI: 10.1053/j.semdp.2019.07.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
18 Kim SC, Foley DP. Donor-specific antibodies in liver transplantation: challenges in diagnosis and determining clinical impact. Curr Opin Organ Transplant 2020;25:549-54. [PMID: 33105198 DOI: 10.1097/MOT.0000000000000825] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Kim PT, Demetris AJ, O'Leary JG. Prevention and treatment of liver allograft antibody-mediated rejection and the role of the 'two-hit hypothesis'. Curr Opin Organ Transplant 2016;21:209-18. [PMID: 26918881 DOI: 10.1097/MOT.0000000000000275] [Cited by in Crossref: 39] [Cited by in F6Publishing: 3] [Article Influence: 6.5] [Reference Citation Analysis]
20 Dao M, Habès D, Taupin JL, Mussini C, Redon MJ, Suberbielle C, Jacquemin E, Gonzales E, Guettier C. Morphological characterization of chronic antibody-mediated rejection in ABO-identical or ABO-compatible pediatric liver graft recipients. Liver Transpl 2018;24:897-907. [PMID: 29704327 DOI: 10.1002/lt.25187] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
21 Demetris AJ, Bellamy CO, Gandhi CR, Prost S, Nakanuma Y, Stolz DB. Functional Immune Anatomy of the Liver-As an Allograft. Am J Transplant. 2016;16:1653-1680. [PMID: 26848550 DOI: 10.1111/ajt.13749] [Cited by in Crossref: 50] [Cited by in F6Publishing: 37] [Article Influence: 8.3] [Reference Citation Analysis]
22 Schiano TD, Florman S, Fiel MI. Recurrent Idiopathic Liver Allograft Failure. Am J Clin Pathol 2019;152:369-76. [PMID: 31139817 DOI: 10.1093/ajcp/aqz044] [Reference Citation Analysis]
23 Kim H, Yi N, Song EY, Lee K, Lee K, Lee HW, Ahn HY, Yoon KC, Hong SK, Suh K. Preformed donor-specific antibodies do not affect the 1-year allograft survival in living donor liver transplantation. Clin Transplant 2018;32:e13244. [DOI: 10.1111/ctr.13244] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
24 Tran L, Humar A. Tolerance studies in liver transplantation: are we fooling ourselves? Current Opinion in Organ Transplantation 2020;25:151-7. [DOI: 10.1097/mot.0000000000000738] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
25 Angelico R, Sensi B, Manzia TM, Tisone G, Grassi G, Signorello A, Milana M, Lenci I, Baiocchi L. Chronic rejection after liver transplantation: Opening the Pandora’s box. World J Gastroenterol 2021; 27(45): 7771-7783 [PMID: 34963740 DOI: 10.3748/wjg.v27.i45.7771] [Reference Citation Analysis]
26 O'leary JG, Demetris AJ, Philippe A, Freeman R, Cai J, Heidecke H, Smith C, Hart B, Jennings LW, Catar R, Everly M, Klintmalm GB, Dragun D. Non-HLA Antibodies Impact on C4d Staining, Stellate Cell Activation and Fibrosis in Liver Allografts. Transplantation 2017;101:2399-409. [DOI: 10.1097/tp.0000000000001853] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 4.8] [Reference Citation Analysis]
27 Kelly D, Verkade HJ, Rajanayagam J, Mckiernan P, Mazariegos G, Hübscher S. Late graft hepatitis and fibrosis in pediatric liver allograft recipients: Current concepts and future developments. Liver Transpl 2016;22:1593-602. [DOI: 10.1002/lt.24616] [Cited by in Crossref: 69] [Cited by in F6Publishing: 46] [Article Influence: 11.5] [Reference Citation Analysis]
28 Sultani B, Marget M, Briem-Richter A, Herrmann J, Meisner S, Grabhorn EF, Ozga AK, Weidemann S, Herden U, Fischer L, Sterneck M. Presence of donor specific HLA class 2 antibodies (DSA class 2) is associated with development of graft fibrosis more than 10 years after liver transplantation-a retrospective single center study. Clin Transplant 2021;35:e14336. [PMID: 33949011 DOI: 10.1111/ctr.14336] [Reference Citation Analysis]
29 Baba HA, Theurer S, Canbay A, Schwertheim S, Lainka E, Kälsch J, Wohlschläger J. [Liver transplantation. Current aspects of pretransplantation diagnosis and rejection]. Pathologe 2020;41:505-14. [PMID: 32776226 DOI: 10.1007/s00292-020-00813-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Kamar N. Donor-specific antibodies and liver transplantation. Hum Immunol. 2016; Feb 23. [Epub ahead of print]. [PMID: 26916836 DOI: 10.1016/j.humimm.2016.02.006] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 5.7] [Reference Citation Analysis]
31 Del Bello A, Danjoux M, Congy-jolivet N, Lavayssière L, Esposito L, Muscari F, Kamar N. Histological long-term outcomes from acute antibody-mediated rejection following ABO-compatible liver transplantation: Outcome of antibody mediated rejection. Journal of Gastroenterology and Hepatology 2017;32:887-93. [DOI: 10.1111/jgh.13613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
32 Levitsky J, O'Leary JG, Asrani S, Sharma P, Fung J, Wiseman A, Niemann CU. Protecting the Kidney in Liver Transplant Recipients: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice. Am J Transplant 2016;16:2532-44. [PMID: 26932352 DOI: 10.1111/ajt.13765] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
33 Wesson RN, Etchill EW, Garonzik-Wang J. Application and interpretation of histocompatibility data in liver transplantation. Curr Opin Organ Transplant. 2017;22:499-504. [PMID: 28708813 DOI: 10.1097/mot.0000000000000450] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
34 Brown RM, Hübscher SG. Role of Histology Following Pediatric Liver Transplantation. Pediatric Liver Transplantation. Elsevier; 2021. pp. 223-32. [DOI: 10.1016/b978-0-323-63671-1.00024-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Sakamoto S, Akamatsu N, Hasegawa K, Ohdan H, Nakagawa K, Egawa H. The efficacy of rituximab treatment for antibody-mediated rejection in liver transplantation: A retrospective Japanese nationwide study. Hepatol Res 2021;51:990-9. [PMID: 33818877 DOI: 10.1111/hepr.13643] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
36 Yamada Y, Hoshino K, Oyanagi T, Gatayama R, Maeda J, Katori N, Fuchimoto Y, Hibi T, Shinoda M, Matsubara K, Obara H, Aeba R, Kitagawa Y, Yamagishi H, Kuroda T. Successful management of living donor liver transplantation for biliary atresia with single ventricle physiology-from peri-transplant through total cavopulmonary connection: A case report. Pediatr Transplant 2018;22:e13118. [PMID: 29457852 DOI: 10.1111/petr.13118] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
37 O'Leary JG, Smith C, Cai J, Hart B, Jennings LW, Everly M, Klintmalm GB, Demetris AJ. Chronic AMR in Liver Transplant: Validation of the 1-Year cAMR Score's Ability to Determine Long-term Outcome. Transplantation 2017;101:2062-70. [PMID: 28452922 DOI: 10.1097/TP.0000000000001802] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
38 Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016;31:149-162. [PMID: 27322218 DOI: 10.1002/jca.21470] [Cited by in Crossref: 168] [Cited by in F6Publishing: 216] [Article Influence: 33.6] [Reference Citation Analysis]
39 Wozniak LJ, Venick RS. Donor-specific antibodies following liver and intestinal transplantation: Clinical significance, pathogenesis and recommendations. International Reviews of Immunology 2019;38:106-17. [DOI: 10.1080/08830185.2019.1630404] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
40 Aday AW, O'Leary JG. Donor-Specific Antibodies' Meaningful Impact on Liver Transplantation. Liver Transpl 2018;24:999-1000. [PMID: 30028076 DOI: 10.1002/lt.25299] [Reference Citation Analysis]
41 Wadström J, Ericzon BG, Halloran PF, Bechstein WO, Opelz G, Serón D, Grinyó J, Loupy A, Kuypers D, Mariat C, Clancy M, Jardine AG, Guirado L, Fellström B, O'Grady J, Pirenne J, O'Leary JG, Aluvihare V, Trunečka P, Baccarani U, Neuberger J, Soto-Gutierrez A, Geissler EK, Metzger M, Gray M. Advancing Transplantation: New Questions, New Possibilities in Kidney and Liver Transplantation. Transplantation 2017;101 Suppl 2S:S1-S41. [PMID: 28125449 DOI: 10.1097/TP.0000000000001563] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.8] [Reference Citation Analysis]
42 Demetris AJ, Bellamy C, Hübscher SG, O’Leary J, Randhawa PS, Feng S, Neil D, Colvin RB, McCaughan G, Fung JJ. 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. Am J Transplant. 2016; Epub ahead of print. [PMID: 27273869 DOI: 10.1111/ajt.13909] [Cited by in Crossref: 230] [Cited by in F6Publishing: 187] [Article Influence: 38.3] [Reference Citation Analysis]
43 Baas M, Gouw ASH, van den Heuvel MC, Hepkema BG, Peeters PMGJ, Verkade H, Scheenstra R. Unique clinical conditions associated with different acinar regions of fibrosis in long-term surviving pediatric liver grafts. Pediatr Transplantation 2017;21:e12988. [DOI: 10.1111/petr.12988] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
44 Neuberger JM, Bechstein WO, Kuypers DR, Burra P, Citterio F, De Geest S, Duvoux C, Jardine AG, Kamar N, Krämer BK, Metselaar HJ, Nevens F, Pirenne J, Rodríguez-Perálvarez ML, Samuel D, Schneeberger S, Serón D, Trunečka P, Tisone G, van Gelder T. Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group. Transplantation 2017;101:S1-S56. [PMID: 28328734 DOI: 10.1097/TP.0000000000001651] [Cited by in Crossref: 114] [Cited by in F6Publishing: 43] [Article Influence: 22.8] [Reference Citation Analysis]
45 Cheng EY. The Role of Humoral Alloreactivity in Liver Transplantation: Lessons Learned and New Perspectives. J Immunol Res. 2017;2017:3234906. [PMID: 28164136 DOI: 10.1155/2017/3234906] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
46 Hogen R, DiNorcia J, Dhanireddy K. Antibody-mediated rejection: what is the clinical relevance? Curr Opin Organ Transplant 2017;22:97-104. [PMID: 28060025 DOI: 10.1097/MOT.0000000000000391] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
47 Lee M. Antibody-Mediated Rejection After Liver Transplant. Gastroenterology Clinics of North America 2017;46:297-309. [DOI: 10.1016/j.gtc.2017.01.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
48 San Segundo D, Alonso C, Ruiz P, Romon I, Arias-Loste MT, Cuadrado A, Puente A, Casafont F, López-Hoyos M, Crespo J, Fábrega E. De Novo Donor-Specific Anti-Human Leukocyte Antigen Antibody Detection in Long-Term Adult Liver Transplantation. Transplant Proc 2016;48:2980-2. [PMID: 27932124 DOI: 10.1016/j.transproceed.2016.08.037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
49 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol 2018; 24(16): 1795-1802 [PMID: 29713132 DOI: 10.3748/wjg.v24.i16.1795] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
50 Han JL, Beal EW, Mumtaz K, Washburn K, Black SM. Combined liver-lung transplantation: Indications, outcomes, current experience and ethical Issues. Transplantation Reviews 2019;33:99-106. [DOI: 10.1016/j.trre.2018.11.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
51 Neves Souza L, de Martino RB, Sanchez-fueyo A, Rela M, Dhawan A, O'grady J, Heaton N, Quaglia A. Histopathology of 460 liver allografts removed at retransplantation: A shift in disease patterns over 27 years. Clin Transplant 2018;32:e13227. [DOI: 10.1111/ctr.13227] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
52 Voutilainen SH, Kosola SK, Lohi J, Jahnukainen T, Pakarinen MP, Jalanko H. Expression of fibrosis-related genes in liver allografts: Association with histology and long-term outcome after pediatric liver transplantation. Clin Transplant 2021;:e14373. [PMID: 34043847 DOI: 10.1111/ctr.14373] [Reference Citation Analysis]
53 Koo J, Wang HL. Acute, Chronic, and Humoral Rejection. Surgical Pathology Clinics 2018;11:431-52. [DOI: 10.1016/j.path.2018.02.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]